These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Immunochemotherapy of a murine thymoma with the use of idarubicin monoclonal antibody conjugates.
    Author: Pietersz GA, Smyth MJ, McKenzie IF.
    Journal: Cancer Res; 1988 Feb 15; 48(4):926-31. PubMed ID: 3422182.
    Abstract:
    Idarubicin is a derivative of daunomycin and is characterized by the absence of the methoxyl group at the C-4 position. It has been reported to have greater therapeutic effect than daunomycin. Idarubicin was chemically coupled to a monoclonal antibody to the murine Ly-2.1 alloantigen and the cytotoxicity of the drug-monoclonal antibody conjugate versus free idarubicin was tested in vitro against Ly-2+ and Ly-2- tumor cell lines. Some loss of idarubicin activity occurred upon conjugation to the monoclonal antibody; however, antibody activity was preserved and selective cytotoxicity for the Ly-2+ cell line was observed. By contrast free idarubicin was equally cytotoxic for all cell lines (Ly-2+ and Ly-2-). Idarubicin-anti-Ly-2.1 conjugates were tested for their capacity to inhibit solid tumor growth in (Ly-2.1-, Ly-2.2+) (C57BL/6 x BALB/c)F1 mice while their nonspecific effects were monitored by histological examination. The idarubicin-anti-Ly-2.1 conjugates when injected i.v. or directly into the tumor were observed to inhibit tumor growth more effectively than idarubicin or anti-Ly-2.1 alone, with smaller tumors being completely eradicated within several days of the completion of treatment.
    [Abstract] [Full Text] [Related] [New Search]